Biocon to Re-Submit Biosimilar Applications to EMA

Drug GMP Report
Biocon said it plans to re-submit applications for European approval of two cancer-treatment biosimilars as soon as it corrects serious GMP deficiencies found at a Bangalore manufacturing plant. The company said it intends to fix the problems by Sept. 30.

To View This Article:


Subscribe To Drug GMP Report